AMSBIO expand range of Laminin isoforms
Designed to efficiently induce differentiation in ES and iPS cells, AMSBIO (Oxford, UK) has expanded its iMatrix series of recombinant laminin E8 fragments to now include isoforms LN-111 and LN-332.
This expanded range of laminin isoforms (LN-111, 332, 511, 411 and 221) now provides even greater flexibility and control when tailoring your substrate to the requirements of specific cultured cells.
Proven in many leading life science research labs – iMatrix is used as a substrate for culturing and maintaining cells, including Pluripotent Stem Cells and Mesenchymal Stem Cells, as well as for differentiation into ectoderm, endoderm, and mesoderm. All iMatrix products offer the dual advantage of recombinant protein expression and as E8 fragments they contain all of the integrin-binding sites of full-length laminin in a much shorter protein.
New to the product range, iMatrix-111 is the E8 fragment of the LN-111 isoform, which plays significant roles in vivo and is important in cell culture. As well as being the major substrate for nerve axon growth, both in vivo and in vitro, LN-111 is also the main component of the industry standard substrates used in cell culture: Matrigel® and Cultrex® BME. iMatrix-111 has been validated for to promote differentiation of iPSCs into hepatocyte-like cells.
The Laminin-332 isoform is essential for epithelial cell adhesion to the basement membrane and iMatrix Laminin-322 has been used to induce differentiation of iPS cells into corneal epithelial cells in vitro.
For further information please visit https://www.amsbio.com/imatrix-recombinant-laminin-series/ or contact AMSBIO on +31-72-8080244 / +44-1235-828200 / +1-617-945-5033 / [email protected]. AMSBIO offers a comprehensive range of synergistic high performance stem cell products for streamlined and efficient ES/iPS cell culture for basic to clinical research – see https://www.amsbio.com/stem-cell-synergy/
About AMSBIO
Founded in 1987, AMS Biotechnology (AMSBIO) is recognized today as a leading transatlantic company contributing to the acceleration of discovery through the provision of cutting-edge life science technology, products and services for research and development in the medical, nutrition, cosmetics, and energy industries. AMSBIO has in-depth expertise in extracellular matrices to provide elegant solutions for studying cell motility, migration, invasion, and proliferation. This expertise in cell culture and the ECM allows AMSBIO to partner with clients in tailoring cell systems to enhance organoid and spheroid screening outcomes using a variety of 3D culture systems, including organ-on-a-chip microfluidics. For drug discovery research, AMSBIO offers assays, recombinant proteins, and cell lines. Drawing upon a huge and comprehensive biorepository, AMSBIO is widely recognised as a leading provider of high-quality tissue specimens (including custom procurement) from both human and animal tissues. The company provides unique clinical grade products for stem cell and cell therapy applications. This includes GMP cryopreservation technology, and high-quality solutions for viral delivery (lentivirus, adenovirus, and adeno-associated virus.
